➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Express Scripts
Mallinckrodt
Medtronic
Boehringer Ingelheim

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for ASP2215


Email this page to a colleague

« Back to Dashboard

What is the drug development status for ASP2215?

ASP2215 is an investigational drug.

There have been 21 clinical trials for ASP2215. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2017.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Astellas Pharma Global Development, Inc., Astellas Pharma Inc, and National Cancer Institute (NCI).

There are thirty US patents protecting this investigational drug and two hundred and fifty-seven international patents.

Recent Clinical Trials for ASP2215
TitleSponsorPhase
A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal FunctionAstellas Pharma Global Development, Inc.Phase 1
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationNational Cancer Institute (NCI)Phase 1
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationCity of Hope Medical CenterPhase 1

See all ASP2215 clinical trials

Clinical Trial Summary for ASP2215

Top disease conditions for ASP2215
Top clinical trial sponsors for ASP2215

See all ASP2215 clinical trials

US Patents for ASP2215

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASP2215   Get Started Free Substituted urea derivatives and pharmaceutical uses thereof SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)   Get Started Free
ASP2215   Get Started Free SYK inhibitors GILEAD SCIENCES, INC. (Foster City, CA)   Get Started Free
ASP2215   Get Started Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Get Started Free
ASP2215   Get Started Free Chemokine receptor modulators and uses thereof FLX Bio, Inc. (South San Francisco, CA)   Get Started Free
ASP2215   Get Started Free Chemokine receptor modulators and uses thereof FLX BIO, INC. (South San Francisco, CA)   Get Started Free
ASP2215   Get Started Free Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ASP2215

Drugname Country Document Number Estimated Expiration Related US Patent
ASP2215 Australia AU2015291522 2034-07-17   Get Started Free
ASP2215 Canada CA2952083 2034-07-17   Get Started Free
ASP2215 China CN105272930 2034-07-17   Get Started Free
ASP2215 Denmark DK3169671 2034-07-17   Get Started Free
ASP2215 European Patent Office EP3169671 2034-07-17   Get Started Free
ASP2215 Spain ES2747249 2034-07-17   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Mallinckrodt
Johnson and Johnson
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.